Advances in cancer medicine have traditionally come from detailed understanding of biological processes, later translated into therapeutic interventions, whose effectiveness is established by rigorous analysis of clinical trials. Over the last two decades the increasing throughput of data from microarray screening, spectral imaging and longitudinal studies are turning the understanding of cancer pathology into as much a data-based as a biologically and clinically driven science, with potential to impact more strongly on evidence-based decision support moving towards personalized medicine [1].